SVRA logo

Savara Inc. Stock Price

NasdaqGS:SVRA Community·US$1.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

SVRA Share Price Performance

US$5.14
2.37 (85.56%)
US$5.14
2.37 (85.56%)
Price US$5.14

SVRA Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with high growth potential.

2 Risks
1 Reward

Savara Inc. Key Details

US$0

Revenue

US$81.4m

Cost of Revenue

-US$81.4m

Gross Profit

US$37.4m

Other Expenses

-US$118.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.47
0%
0%
14.7%
View Full Analysis

About SVRA

Founded
2007
Employees
70
CEO
Matthew Pauls
WebsiteView website
www.savarapharma.com

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Recent SVRA News & Updates

Recent updates

No updates